Subgroup analyses stratified by gender and age.

<div><p>Background</p><p>Sodium zirconium cyclosilicate (SZC, Lokelma) is a novel hyperkalemia therapy, but comprehensive real-world safety data are lacking. This study aimed to characterize SZC-associated adverse events (AEs) using post-marketing surveillance.</p><p...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Yinrui Fang (22169878) (author)
مؤلفون آخرون:	Zilun Wu (18696883) (author), Qian Wu (209382) (author), Gangyi Chen (381813) (author)
منشور في:	2025
الموضوعات:	Medicine Cell Biology Genetics Neuroscience Pharmacology Biotechnology Evolutionary Biology Immunology Developmental Biology Cancer Mental Health Infectious Diseases Virology world safety data sodium zirconium cyclosilicate g ., ileus four disproportionality algorithms associated adverse events 564 ae reports 2004 &# 8211 term risks remain novel hyperkalemia therapy identified safety signals cardiac adverse events previously unreported aes aes peaked early signals met previously recognized preferred term initial therapy early phase xlink "> ventricular fibrillation using post study highlights study aimed research design prospective studies inherent constraints general disorders findings suggest cardiac failure algorithm thresholds 2023 ).
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

Subgroup analyses stratified by gender and age.

مواد مشابهة